Human PAI-1 (wild type active fraction)


SKU: PAI-A Categories: ,

Product Description

Human wild type PAI-1 is produced as an active and latent form in E. Coli. The purification conditions are gentle and result in an active fraction >99percent pure and >98percent active as determined by titration with HMW tc-urokinase and SDS PAGE.

Gene ID: 5054
Swiss-Prot/UniProt ID: P05121

View sample datasheet
View sample certificate of analysis
View material safety data sheet
Ask a question about this product

Additional Information



Molecular Weight

Extinction Coefficient



Shipping Conditions




Sample Size

Sample Concentration

Sample Volume

Gene Name

Gene ID

UniProt ID

1. Iafrati MD, Vitseva O, Tanriverdi K et-al. Compensatory mechanisms influence hemostasis in setting of eNOS deficiency. Am. J. Physiol. Heart Circ. Physiol. 2005;288 (4): H1627-32. doi:10.1152/ajpheart.00819.2004Pubmed citation

2. Jo M, Thomas KS, Marozkina N et-al. Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator. J. Biol. Chem. 2005;280 (17): 17449-57. doi:10.1074/jbc.M413141200Pubmed citation

3. Chai J, Charboneau AL, Betz BL et-al. Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells. Cancer Res. 2005;65 (22): 10192-8. doi:10.1158/0008-5472.CAN-05-1896Pubmed citation

4. Chu JW, Abbasi F, Lamendola C et-al. Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects. Diab Vasc Dis Res. 2005;2 (1): 37-41. doi:10.3132/dvdr.2005.004Pubmed citation

5. Moran P, Li W, Fan B et-al. Pro-urokinase-type plasminogen activator is a substrate for hepsin. J. Biol. Chem. 2006;281 (41): 30439-46. doi:10.1074/jbc.M605440200Pubmed citation

6. O’connor JC, Farach-carson MC, Schneider CJ et-al. Coculture with prostate cancer cells alters endoglin expression and attenuates transforming growth factor-beta signaling in reactive bone marrow stromal cells. Mol. Cancer Res. 2007;5 (6): 585-603. doi:10.1158/1541-7786.MCR-06-0408Pubmed citation

7. Inagi R, Izuhara Y, Tominaga N et-al. Establishment of a sandwich ELISA for human megsin, a kidney-specific serine protease inhibitor. Nephrol. Dial. Transplant. 2007;22 (11): 3311-7. doi:10.1093/ndt/gfm391Pubmed citation

8. Norris EH, Strickland S. Modulation of NR2B-regulated contextual fear in the hippocampus by the tissue plasminogen activator system. Proc. Natl. Acad. Sci. U.S.A. 2007;104 (33): 13473-8. doi:10.1073/pnas.0705848104Free text at pubmedPubmed citation

9. Schar CR, Blouse GE, Minor KH et-al. A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activity. J. Biol. Chem. 2008;283 (16): 10297-309. doi:10.1074/jbc.M708017200Free text at pubmedPubmed citation

10. Li SH, Gorlatova NV, Lawrence DA et-al. Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands. J. Biol. Chem. 2008;283 (26): 18147-57. doi:10.1074/jbc.M709455200Free text at pubmedPubmed citation

11. Vial D, Mckeown-longo PJ. PAI1 stimulates assembly of the fibronectin matrix in osteosarcoma cells through crosstalk between the alphavbeta5 and alpha5beta1 integrins. J. Cell. Sci. 2008;121 (Pt 10): 1661-70. doi:10.1242/jcs.020149Free text at pubmedPubmed citation

12. Chen SC, Henry DO, Reczek PR et-al. Plasminogen activator inhibitor-1 inhibits prostate tumor growth through endothelial apoptosis. Mol. Cancer Ther. 2008;7 (5): 1227-36. doi:10.1158/1535-7163.MCT-08-0051Pubmed citation

13. Lund IK, Jögi A, Rønø B et-al. Antibody-mediated targeting of the urokinase-type plasminogen activator proteolytic function neutralizes fibrinolysis in vivo. J. Biol. Chem. 2008;283 (47): 32506-15. doi:10.1074/jbc.M801924200Pubmed citation

14. Adair JE, Stober V, Sobhany M et-al. Inter-alpha-trypsin inhibitor promotes bronchial epithelial repair after injury through vitronectin binding. J. Biol. Chem. 2009;284 (25): 16922-30. doi:10.1074/jbc.M808560200Free text at pubmedPubmed citation

15. Fjellström O, Deinum J, Sjögren T et-al. Characterization of a small molecule inhibitor of plasminogen activator inhibitor type 1 that accelerates the transition into the latent conformation. J. Biol. Chem. 2013;288 (2): 873-85. doi:10.1074/jbc.M112.371732Free text at pubmedPubmed citation

16. Florova G, Karandashova S, Declerck PJ et-al. Remarkable stabilization of plasminogen activator inhibitor 1 in a “molecular sandwich” complex. Biochemistry. 2013;52 (27): 4697-709. doi:10.1021/bi400470sFree text at pubmedPubmed citation

17. Boe AE, Eren M, Murphy SB et-al. Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence. Circulation. 2013;128 (21): 2318-24. doi:10.1161/CIRCULATIONAHA.113.003192Free text at pubmedPubmed citation

18. Komissarov AA, Florova G, Azghani A et-al. Active α-macroglobulin is a reservoir for urokinase after fibrinolytic therapy in rabbits with tetracycline-induced pleural injury and in human pleural fluids. Am. J. Physiol. Lung Cell Mol. Physiol. 2013;305 (10): L682-92. doi:10.1152/ajplung.00102.2013Free text at pubmedPubmed citation

19. Damare J, Brandal S, Fortenberry YM. Inhibition of PAI-1 antiproteolytic activity against tPA by RNA aptamers. Nucleic Acid Ther. 2014;24(4):239-49. Link to article

20. Komissarov AA, Florova G, Azghani AO, et al. The time course of resolution of adhesions during fibrinolyitic therapy in tetracycline-induced pleural injury in rabbits. Am J Physiol Lung Cell Mol Physiol. 2015;:ajplung.00136.2015. link to article

21. Florova G, Azghani AO, Karandashova S, et al. Targeting Plasminogen Activator Inhibitor 1 in Tetracycline-Induced Pleural Injury in Rabbits. Am J Physiol Lung Cell Mol Physiol. 2017;:ajplung.00579.2016. Link to article

You may also like…